• Home
  • Search Results
  • Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation.

Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation.

Nature immunology (2008-04-29)
Peter R Wilker, Masako Kohyama, Michelle M Sandau, Jörn C Albring, Osamu Nakagawa, John J Schwarz, Kenneth M Murphy

Calcineurin is required for B cell receptor (BCR)-induced proliferation of mature B cells. Paradoxically, loss of NFAT transcription factors, themselves calcineurin targets, induces hyperactivity, which suggests that calcineurin targets other than NFAT are required for BCR-induced proliferation. Here we demonstrate a function for the calcineurin-regulated transcription factor Mef2c in B cells. BCR-induced calcium mobilization was intact after Mef2c deletion, but loss of Mef2c caused defects in B cell proliferation and survival after BCR stimulation in vitro and lower T cell-dependent antibody responses and germinal center formation in vivo. Mef2c activity was specific to BCR stimulation, as Toll-like receptor and CD40 signaling induced normal responses in Mef2c-deficient B cells. Mef2c-dependent targets included the genes encoding cyclin D2 and the prosurvival factor Bcl-x(L). Our results emphasize an unrecognized but critical function for Mef2c in BCR signaling.

Product Number
Product Description

Triton X-100, laboratory grade
Triton X-100, for molecular biology
Triton X-100, BioXtra
Ionomycin from Streptomyces conglobatus, ≥98% (HPLC)
5(6)-Carboxyfluorescein diacetate N-succinimidyl ester, BioReagent, suitable for fluorescence, ≥90% (HPLC)
Blood Agar (Base), suitable for microbiology, NutriSelect® Plus
Triton X-100, peroxide- and carbonyl-free

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.